KRAS and cancer: Indeed, research has shown that KRAS mutant cancer cells are highly sensitive to PLK1 inhibition [12], wherein cancer cells carrying the oncogenic mutation KRAS were sensitive to PLK1 depletion by shRNA or to treatment with PLK1 inhibitors.